Infensa wins KE Select Emerging Innovator of the Year at Life Sciences Queensland awards

(L-R) Sarah Meibusch, Life Sciences Queensland Director; Associate Professor Nathan Palpant, Infensa Head of Biology; Professor Glenn King, Infensa Chief Scientific Officer; Associate Professor Mark Smythe, Infensa CEO; Kerry McMahon, KE Select Managing Director.

The Infensa Bioscience team was jumping for joy when we won the KE Select Emerging Innovator Award at the Life Sciences Queensland Ltd (LSQ) GENE Awards, which recognise individuals and organisations from the Queensland life sciences sector.

The KE Select Emerging Innovator Award recognises early-stage ventures that have "shown remarkable dedication and innovation in their research and development". We were humbled and delighted to receive this award for our work developing game-changing therapies for two of the leading causes of death worldwide: stroke and heart attack.

Our team are no strangers to these awards; last year, CEO Mark Smythe took out the Industry Excellence Award, which celebrates an individual who has made a significant impact on the success of the Queensland life sciences industry.

One of the companies Mark has previously founded, Protagonist Therapeutics, was a finalist in this year’s GENE Awards in the LSQ Cytiva Company of the Year category.

Thank you to Life Sciences Queensland for celebrating the state’s life sciences community, KE Select - Scientific & Medical Recruitment Specialists for their support of the Emerging Innovators Award and congratulations to the rest of our team: Professor Glenn King, Associate Professor Nathan Palpant, Louisa Carey, Dr Michael Ankersen, Ming Chong, Dr Aline Dantas de Araujo, Dr Han Chiu, Dr Han Siean Lee, and Dr Natalie Saez.